We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Mutation Testing Utilized in Anaplastic Thyroid Cancer

By LabMedica International staff writers
Posted on 26 Aug 2022
Print article
Image: Histology of anaplastic thyroid carcinoma that features cellular pleomorphism, large atypical cells, myxoid degeneration, and bizarre giant cells (Photo courtesy of Cesar A. Moran, MD).
Image: Histology of anaplastic thyroid carcinoma that features cellular pleomorphism, large atypical cells, myxoid degeneration, and bizarre giant cells (Photo courtesy of Cesar A. Moran, MD).

Mutations in two key oncogenes are associated with patient outcomes in anaplastic thyroid carcinoma (ATC), pointing to the utility of tumor mutation testing during treatment decision making for individuals with the disease.

ATC, a rare but deadly form of thyroid cancer, has been shown to be genetically heterogeneous, but the clinical significance of the cancer's different mutation profiles has not been closely examined. ATC is characterized by advanced disease at presentation and rapid progression within weeks.

Medical Oncologists at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) and their associates performed mutation sequencing using targeted gene panels on 202 ATC patients and found that the cancer can be divided into three subtypes based on mutually exclusive driver mutations in the genes BRAF and RAS.

Tumor materials obtained from fine needle biopsy, core biopsy, excisional biopsy, or surgical resection were used for mutational testing. Paired stained slides were used to identify tumor regions of interest and assess for tumor cellularity (>20%). NGS was performed with a minimum depth of approximately 250×. Where blood samples were available, gene panels incorporating germline variant subtractions were used including Solid Tumor Genomic Assay V1 (128 genes), Solid Tumor Genomics Assay 2018 (134 genes), and MDA-409 (409 genes) which detected SNVs and indels. NGS of liquid biopsy samples was performed on circulating cell free DNA (cfDNA) using a validated 70-gene panel (LB70), which detects SNVs and indels in 70 genes.

The investigators reported that a total of 202 patients were included, and 122 died of ATC (60%). The median follow-up was 31 months (interquartile range, 18-45 months). The most common mutations were in TP53 (59%), BRAF (41%), TERT promoter (37%), and the RAS gene family (22%). Clinicopathologic characteristics and overall survival (OS) significantly correlated with mutations in BRAFV600E and RAS, which were mutually exclusive. The BRAFV600E mutation was associated with the presence of a papillary thyroid carcinoma precursor and significantly better overall survival (median OS: 24 months). RAS-mutated patients more commonly presented without cervical lymph node involvement, but had the worst OS (median OS: 6 months). Tumors that were wild-type for both BRAF and RAS were enriched for NF1 mutations and harbored intermediate prognosis (median OS: 15 months).

The authors concluded that driver mutations in ATC are associated with distinct clinicopathologic features and survival outcomes, reflecting heterogeneity in tumor biology. Although treatment with BRAF/MEK inhibitors can be initiated on the basis of knowledge of BRAFV600E status alone (i.e., using immunohistochemistry), knowledge of RAS and TP53 mutation status allows for additional risk stratification and can guide further therapeutic decision making. As such, comprehensive tumor mutation profiling should be obtained for patients with ATC as a part of the routine clinical workup at diagnosis. The study was published on August 17, 2022 in the journal JCO Precision Oncology.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.